Home  >  MEDTECH  > Quantapore closed a Series B with a total investment volume ...
May 21st, 2014
Quantapore closed a Series B with a total investment volume of up to $35M from undisclosed investors
Quantapore Inc. is developing a novel, nanopore based nucleic acid sequencing technology.
Send to a friend

Unlike other nanopore approaches, Quantapore utilizes an optical read out which results in lower cost and higher throughput compared to electrical data acquisition.

Funds will be used to finalize the development of Quantapore’s proprietary sequencing technology as well as the commercialization of its sequencing platform.

More MEDTECH news

Aug 23rd
Aug 21st
Aug 21st
Aug 21st
Aug 13th
©2007 Yole Developpement All rights reserved                  Disclaimer | Legal notice | To advertise
Yole Développement: Le Quartz, 75 cours Emile Zola, 69100 Villeurbanne, France. TEL: (33) 472 83 01 80 FAX: (33) 472 83 01 83 E-Mail: info @yole.fr